Chinese biotech investors are pouring billions into US companies; Nektar partners with BioXcel on new I/O triple
→ “They said, ‘If you start a company, you won’t have any problem raising money.’ I didn’t quite believe that at the beginning. But as we went through the process, it was incredible,” Brii CEO Zhi Hong told Reuters as the wire service assessed the blistering pace of growth in China’s biotech sector. Hong, an ex-GSK exec, raised $260 million as Chinese investors poured $4.2 billion into U.S. biotechs — 43% of the total for the first half of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
